Compare FLYW & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | AGIO |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2021 | 2013 |
| Metric | FLYW | AGIO |
|---|---|---|
| Price | $18.19 | $34.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | $16.21 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 1.9M | 914.1K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $623,025,000.00 | $43,011,000.00 |
| Revenue This Year | $19.68 | $76.75 |
| Revenue Next Year | $15.25 | $170.73 |
| P/E Ratio | $629.67 | ★ N/A |
| Revenue Growth | ★ 26.59 | N/A |
| 52 Week Low | $10.55 | $22.24 |
| 52 Week High | $19.73 | $46.00 |
| Indicator | FLYW | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 50.18 |
| Support Level | $13.34 | $32.54 |
| Resistance Level | $18.94 | $36.04 |
| Average True Range (ATR) | 0.59 | 1.17 |
| MACD | -0.06 | 0.15 |
| Stochastic Oscillator | 30.04 | 43.71 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.